Scout Investments Inc. Sells 104,199 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) (2024)

Scout Investments Inc. lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 28.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 261,618 shares of the company's stock after selling 104,199 shares during the quarter. Neurocrine Biosciences makes up 0.9% of Scout Investments Inc.'s investment portfolio, making the stock its 28th largest position. Scout Investments Inc. owned about 0.26% of Neurocrine Biosciences worth $34,471,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in NBIX. Headinvest LLC bought a new position in Neurocrine Biosciences in the 3rd quarter worth about $28,000. Lindbrook Capital LLC boosted its position in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company's stock valued at $28,000 after acquiring an additional 96 shares during the last quarter. EdgeRock Capital LLC purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $31,000. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $33,000. Finally, Sunbelt Securities Inc. grew its holdings in shares of Neurocrine Biosciences by 34.3% during the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company's stock worth $37,000 after purchasing an additional 83 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NBIX. UBS Group boosted their price objective on Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a "buy" rating in a report on Tuesday, May 28th. HC Wainwright boosted their price objective on Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a "buy" rating in a report on Thursday, May 2nd. Canaccord Genuity Group boosted their price objective on Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a "buy" rating in a report on Thursday, May 2nd. BMO Capital Markets boosted their price objective on Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a "market perform" rating in a report on Thursday, May 2nd. Finally, Citigroup boosted their price objective on Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a "neutral" rating in a report on Friday, May 3rd. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $150.85.

Check Out Our Latest Research Report on NBIX

Insider Activity at Neurocrine Biosciences

In related news, insider Eric Benevich sold 19,818 shares of the company's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares in the company, valued at $5,438,154.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Stephen A. Sherwin sold 40,000 shares of the company's stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the sale, the director now directly owns 26,504 shares of the company's stock, valued at $3,537,223.84. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric Benevich sold 19,818 shares of the company's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the sale, the insider now directly owns 40,778 shares in the company, valued at $5,438,154.08. The disclosure for this sale can be found here. Insiders sold a total of 208,997 shares of company stock worth $28,773,215 over the last quarter. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock traded up $1.90 during midday trading on Friday, reaching $134.97. 496,138 shares of the company's stock traded hands, compared to its average volume of 771,844. The company has a market cap of $13.58 billion, a PE ratio of 37.18 and a beta of 0.36. The stock has a 50 day moving average of $137.87 and a 200-day moving average of $133.94. Neurocrine Biosciences, Inc. has a 12 month low of $92.61 and a 12 month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing analysts' consensus estimates of $1.04 by ($0.62). The business had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Read More

• Five stocks we like better than Neurocrine Biosciences
• What Are the U.K. Market Holidays? How to Invest and Trade
• MarketBeat Week in Review – 6/3 - 6/7
• Natural Gas Prices Continue To Rally, These Stocks Should Benefit
• Geron Corporation: FDA Approval Fuels Stock Price Surge
• High Flyers: 3 Natural Gas Stocks for March 2022
• Intel's Secret Plan for a Double-Digit Stock Rally Revealed

Should you invest $1,000 in Neurocrine Biosciences right now?

Before you consider Neurocrine Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.

While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here